Abstract 1829P
Background
To investigate the nutritional status of hospitalized patients with common malignant tumor in a cancer hospital of Southwest China.
Methods
From April 2017 to May 2021, we enrolled 891 patients with cancer hospitalized for treatment in Chongqing university Cancer Hospital. These patients were diagnosed with one of the following 16 different types of malignant tumors: lung cancer, gastric cancer, liver cancer, colorectal cancer, breast cancer, esophageal cancer, cervical cancer, endometrial cancer, nasopharyngeal carcinoma, malignant lymphoma, leukemia, pancreatic cancer, ovarian cancer, prostate cancer, bladder cancer and brain tumor. Patient-generated subjective global assessment (PG-SGA), anthropometric measurements, and laboratory examination were used to evaluate the nutritional risk or nutritional status.Cancer pain status were assessed with the Numerical Rating Scale (NRS). We also investigated the nutritional therapy of these cancer patients.
Results
According to the PG-SGA score, 48.7% (434/891) of the cancer patients were severe malnutrition (PG-SGA≥9), 31.2% (312/891) were moderate malnutrition (8≥PG-SGA≥4), 14.7% (131/891) were mild malnutrition (PG-SGA 2∼3), and only 5.4% (48/891) patients were no malnutrition (PG-SGA 0∼1). The rate of malnutrition for gastrointestinal cancer patients is higher than Nongastrointestinal cancer patients (67.3% vs. 44.6%, χ2=31.48, P <0.001). Multiple linear regression analysis, PG-SGA scores and body mass index (P<0.001), serum total protein(P<0.001), hemoglobin serum(P<0.001), albumin (P<0.001), prealbumin (P<0.001), calf circumference (left side, P=0.001) were correlated. Age(≥65 years), albumin(<40g/L), prealbumin (<150mg/L) and cancer pain (NRS≥4) are the risk factors of severe malnutrition. However, only 26.8% (200/746) of all the moderately and severely malnourished patients received nutritional therapy.
Conclusions
94.6% of the common malignant tumor patients enrolled in the present study were malnutrition. Nutritional therapy of malignant tumor patients with malnutrition is very low.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1853P - Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Presenter: David Gandara
Session: Poster session 12
1854P - Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study
Presenter: Kadriye Baskurt
Session: Poster session 12
1855P - Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ)
Presenter: Carolina Navas
Session: Poster session 12
1856P - Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study
Presenter: Javier López Robles
Session: Poster session 12
1857P - Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS)
Presenter: Jerold Loh
Session: Poster session 12
1858P - Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies
Presenter: Nikolaos Tsoukalas
Session: Poster session 12
1860P - The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia
Presenter: Yuanping Hsia
Session: Poster session 12
1861P - Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
Presenter: Manuel Sanchez Canovas
Session: Poster session 12
1862P - A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors
Presenter: Weiwen Zhou
Session: Poster session 12
1863P - Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 12